
Sign up to save your podcasts
Or


In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Sean Werner, Chief Technology Officer at BioLife Solutions,
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sean, covering:
Sean Werner is the Chief Technology Officer at BioLife Solutions, a leading provider of bioproduction tools and services to the cell and gene therapy and broader biopharma markets. BioLife acquired Sexton Biotechnologies in 2021 where Sean was President of the company known for providing processing and handling solutions for the CGT industry. Sean received his PhD from Purdue University in Biology followed by post-doctoral positions at the Indiana University School of Medicine and Eli Lilly. Sean has previous experience filling various roles in the scientific, global regulatory, and general management functions supporting medical devices, autologous cell therapy, and single use disposable development programs. In his 23 years working in the life science industry, he has guided regenerative medicine research programs, pre-clinical and clinical testing and submission strategies leading to global commercialization of medical devices and bioprocessing tools and successful initiation of multi-national cell therapy clinical studies.
Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
By Raman Sehgal5
3535 ratings
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Sean Werner, Chief Technology Officer at BioLife Solutions,
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sean, covering:
Sean Werner is the Chief Technology Officer at BioLife Solutions, a leading provider of bioproduction tools and services to the cell and gene therapy and broader biopharma markets. BioLife acquired Sexton Biotechnologies in 2021 where Sean was President of the company known for providing processing and handling solutions for the CGT industry. Sean received his PhD from Purdue University in Biology followed by post-doctoral positions at the Indiana University School of Medicine and Eli Lilly. Sean has previous experience filling various roles in the scientific, global regulatory, and general management functions supporting medical devices, autologous cell therapy, and single use disposable development programs. In his 23 years working in the life science industry, he has guided regenerative medicine research programs, pre-clinical and clinical testing and submission strategies leading to global commercialization of medical devices and bioprocessing tools and successful initiation of multi-national cell therapy clinical studies.
Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

91,297 Listeners

8,801 Listeners

4,420 Listeners

1,952 Listeners

8,876 Listeners

337 Listeners

176 Listeners

3,051 Listeners

61 Listeners

10,254 Listeners

85 Listeners

15,506 Listeners

187 Listeners

2,536 Listeners

2 Listeners